Literature DB >> 20224882

A case of long-term recurrence-free poorly differentiated neuroendocrine carcinoma of lymph nodes treated by surgical resection without any chemotherapy.

Shigeo Hisamori1, Hiroshi Okabe, Akihiko Yoshizawa, Yoshiharu Sakai.   

Abstract

A 77-year-old man presented with a 2-month history of an enlarged right inguinal lymph node. Diagnostic excisional biopsy of the inguinal lymph node proved it to be a poorly differentiated neuroendocrine carcinoma by histological and immunohistological analyses. We diagnosed a poorly differentiated neuroendocrine carcinoma by histological examination and immunohistological analysis of the resected inguinal lymph node. We performed computed tomographic examination and positron emission tomography, which identified lymph node involvement without any signs of other tumors. Because these tumors had grown expandingly and had been encapsulated locally, we performed an operation to dissect all of the involved lymph nodes. Direct invasion to the right external iliac artery was not detected, and two of the enlarged lymph nodes were successfully resected without any complications. Pathologically, the resected specimen was diagnosed as a neuroendocrine carcinoma with a negative surgical margin and it was similar to the histology of the inguinal lymph node previously resected. The patient had no recurrence for 3 years without receiving any adjuvant treatment. There have been no reports describing a case of poorly differentiated neuroendocrine carcinoma, of unknown origin, which metastasized to other lymph nodes. Although further studies are required, complete resection of the involved lymph nodes should be considered as a choice for localized, expanding growth-pattern disease even if it is undifferentiated type.

Entities:  

Mesh:

Year:  2010        PMID: 20224882     DOI: 10.1007/s10147-010-0058-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  Nodal neuroendocrine (Merkel cell) carcinoma without an identifiable primary tumor.

Authors:  Hiroko Kuwabara; Hiroshi Mori; Hirotsugu Uda; Kiyozumi Takei; Yoshichika Ishibashi; Naotomo Takatani
Journal:  Acta Cytol       Date:  2003 May-Jun       Impact factor: 2.319

Review 2.  Cancer of unknown primary: biological and clinical characteristics.

Authors:  N Pavlidis
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

3.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP).

Authors:  E Briasoulis; C Tolis; J Bergh; N Pavlidis
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

4.  Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

Authors:  Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

5.  Treatment of merkel cell carcinoma.

Authors:  Tony Y Eng; Melisa G K Boersma; Clifton D Fuller; Sean X Cavanaugh; Fabio Valenzuela; Terence S Herman
Journal:  Am J Clin Oncol       Date:  2004-10       Impact factor: 2.339

6.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Authors:  Matthew H Kulke; Keith Stuart; Peter C Enzinger; David P Ryan; Jeffrey W Clark; Alona Muzikansky; Michele Vincitore; Ann Michelini; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

Review 7.  The role of nuclear medicine in the diagnosis of cancer of unknown origin.

Authors:  H Demir; F Berk; M Raderer; P N Plowman; U Lassen; G Daugaard; M Clausen; K H Bohuslavizki; M Peters; C Harmer; J Malamitsi; C Aktolun
Journal:  Q J Nucl Med Mol Imaging       Date:  2004-06       Impact factor: 2.346

8.  Neuroendocrine carcinoma within lymph nodes in the absence of a primary tumor, with special reference to Merkel cell carcinoma.

Authors:  V Eusebi; C Capella; A Cossu; J Rosai
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

9.  Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.

Authors:  Xiaoqi Lin; Reda S Saad; Todd M Luckasevic; Jan F Silverman; Yulin Liu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-12

10.  Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.

Authors:  E Briasoulis; G Fountzilas; A Bamias; M A Dimopoulos; N Xiros; G Aravantinos; E Samantas; H Kalofonos; T Makatsoris; N Mylonakis; P Papakostas; D Skarlos; I Varthalitis; N Pavlidis
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-28       Impact factor: 3.333

View more
  1 in total

1.  Poorly differentiated neuroendocrine carcinoma in a perigastric lymph node from an unknown primary site.

Authors:  Hee Seung Lee; Hye-Suk Han; Sung-Nam Lim; Hyun-Jung Jeon; Ho-Chang Lee; Ok-Jun Lee; Hyo Young Yun; Ki Hyeong Lee; Seung Taik Kim
Journal:  Cancer Res Treat       Date:  2012-12-31       Impact factor: 4.679

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.